#

Global Pulmonary Arterial Hypertension (PAH) Market Size, Trends and Forecast Report 2014 – 2025

  • Published Date: May-18
  • 100 Pages
  • Category: Technology
  • Format: Email PDF + Excel
  • Language: ENG
The ‘Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Geography Covered The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan Study Period: 2016-2027 Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm The Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension (PAH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the US, Europe, and Japan. Pulmonary Arterial Hypertension (PAH) Epidemiology The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, and sub-type specific prevalent cases) scenario of Pulmonary Arterial Hypertension (PAH)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. According to the report, the total number of prevalent population of Pulmonary Arterial Hypertension (PAH) was found to be more than 70,000 in 7MM, in the year 2016. Women account for 70% of the total prevalent cases. Pulmonary Arterial Hypertension (PAH) Drug Chapters This segment of the Pulmonary Arterial Hypertension (PAH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Therapeutic market of PAH is dominated with the use of endothelin receptor antagonists, prostanoids, calcium channel blockers, phosphodiesterase inhibitors and Soluble Guanylate Cyclase (sGC) stimulators. Detailed chapters of all these therapies, along with the upcoming therapies such as Aurora-GT ((United Therapeutics Corp.), Tysuberprost (United Therapeutics Corp.) and Macitentan (Actelion Pharmaceuticals Ltd) have been covered in the report. Pulmonary Arterial Hypertension (PAH) Market Outlook The Pulmonary Arterial Hypertension (PAH) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to the report, the global market of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be USD 5.13 Billion in 2016, and is expected to increase from 2016-2027. Pulmonary Arterial Hypertension (PAH) Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Pulmonary Arterial Hypertension (PAH) Report Insights Patient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies Pulmonary Arterial Hypertension (PAH) Report Key Strengths 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Pulmonary Arterial Hypertension (PAH) Report Assessment Current Treatment Practices Unmet Needs Detailed Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers Key Benefits This report will help to develop Business Strategies by understanding the trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market.